SCHEMBL20069578

SCHEMBL20069578

CN1CC2CC(C1)N2C(=O)c1cccnc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.51
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA7 P36544 1/20 0.50
CHRNA4 P43681 1/20 0.50
ALDH1A1 P00352 3/20 0.46
MAPK1 P28482 1/20 0.46
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
GAA P10253 2/20 0.44
APP P05067 1/20 0.44
HCAR3 P49019 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
POLB P06746 1/20 0.43
RIPK1 Q13546 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
STAT3 P40763 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20160461 0.85 PIK3CD (0.48) PIK3CDCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20148706 0.85 PIK3CD (0.54) PIK3CDCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL23555022 0.83 PIK3CD (0.52) PIK3CDCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL21159004 0.83 PIK3CD (0.46) PIK3CDCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20070449 0.82 VNN1 (0.38) GAAHCAR2
SCHEMBL20069586 0.80 HDAC1 (0.43) ALDH1A1LMNA
SCHEMBL22030879 0.80 HCAR2 (0.46) ALDH1A1HCAR2L3MBTL1
SCHEMBL20070453 0.77 RET (0.34) ALDH1A1GAAL3MBTL1STAT3
SCHEMBL22030880 0.77 MGLL (0.46) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL20069582 0.76 SIRT3 (0.46) TDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3753939-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma Inc. (US) 2020-12-23 EP disclosed
EP-3523301-B1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-05-27 EP disclosed
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
WO-2018071447-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10172851-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF PIK3CD 1191/4885CHRNB2 2276/4885CHRNB4 1708/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF PIK3CD 1191/4885CHRNB2 2276/4885CHRNB4 1708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.